Koch leads mammoth $215M infusion into AI startup boasting 'largest database' of immune cells
In the three years since Noam Solomon and Luis Voloch started Immunai, the company has quickly outgrown its digs.
Immunai’s team went from 30 staffers in May 2020 to 120, representing 16 nationalities and spread across five cities — Tel Aviv, New York, San Francisco, Zurich and Prague — after recently acquiring two companies to beef up their database and analytic capabilities. More than 30 groups in biopharma and academia have signed up to use their technologies.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.